Takeover Fever Struck Achillion, but AbbVie’s Still Way Out in Front
Insights - Achillion Pharmaceuticals (ACHN) has been all over the news in the last week (and up more than 100%), the latest target of takeover fever in … Continue Reading
Read NowzFree
More Federal Tax Dollars Slip Away as Medtronic Buys Covidien
Insights - Medtronic (MDT) announced Sunday an agreement to buy Covidien (COV) in a $42.9 billion dollar cash and stock deal. The 29% premium is thought to … Continue Reading
Read Now
bluebird bio’s Treatment for a Rare Blood Disorder is Working
Insights - bluebird bio (BLUE) reported that two patients taking LentiGlobin had rapid and sustained responses to the gene therapy
Read Now
Our Top Stories In Biotech This Week
Recap - Orexigen Therapeutics (OREX) got an unexpected surprise on Wednesday when the FDA extended its review of the New Drug Application for NB32, the company’s investigational drug … Continue Reading
Read Now
How We Spotted This Winning Trade – Before It Happened
zFree - Conatus Pharmaceuticals (CNAT) closed Wednesday up 56% $6.05 on Tuesday $9.48 on Wednesday 56%. In a single session. With no news from Conatus this week and no groundbreaking events anticipated in … Continue Reading
Read Now
Geron Trials Still on Hold While Collaborator Gets the Greenlight
Insights - Geron Corporation (GERN) announced on Thursday that the FDA has lifted a clinical hold on one trial of lead drug candidate, imetelstat, in myelofibrosis. Though … Continue Reading
Read Now
Intercept Isn’t The Only Way to Play Rare Liver Diseases
Research - Intercept (ICPT) jumped to the top of many watchlists when a drug for liver diseases showed success in a P2 trial. Here's another, cheaper idea.
Read Now